Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome
Copyright © 2020 Borghi, Beltagy, Garrafa, Curreli, Cecchini, Bodio, Grossi, Blengino, Tincani, Franceschini, Andreoli, Lazzaroni, Piantoni, Masneri, Crisafulli, Brugnoni, Muiesan, Salvetti, Parati, Torresani, Mahler, Heilbron, Pregnolato, Pengo, Tedesco, Pozzi and Meroni..
Background: Critically ill patients with coronavirus disease 2019 (COVID-19) have a profound hypercoagulable state and often develop coagulopathy which leads to organ failure and death. Because of a prolonged activated partial-thromboplastin time (aPTT), a relationship with anti-phospholipid antibodies (aPLs) has been proposed, but results are controversial. Functional assays for aPL (i.e., lupus anticoagulant) can be influenced by concomitant anticoagulation and/or high levels of C reactive protein. The presence of anti-cardiolipin (aCL), anti-beta2-glycoprotein I (anti-β2GPI), and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies was not investigated systematically. Epitope specificity of anti-β2GPI antibodies was not reported.
Objective: To evaluate the prevalence and the clinical association of aPL in a large cohort of COVID-19 patients, and to characterize the epitope specificity of anti-β2GPI antibodies.
Methods: ELISA and chemiluminescence assays were used to test 122 sera of patients suffering from severe COVID-19. Of them, 16 displayed major thrombotic events.
Results: Anti-β2GPI IgG/IgA/IgM was the most frequent in 15.6/6.6/9.0% of patients, while aCL IgG/IgM was detected in 5.7/6.6% by ELISA. Comparable values were found by chemiluminescence. aPS/PT IgG/IgM were detectable in 2.5 and 9.8% by ELISA. No association between thrombosis and aPL was found. Reactivity against domain 1 and 4-5 of β2GPI was limited to 3/58 (5.2%) tested sera for each domain and did not correlate with aCL/anti-β2GPI nor with thrombosis.
Conclusions: aPL show a low prevalence in COVID-19 patients and are not associated with major thrombotic events. aPL in COVID-19 patients are mainly directed against β2GPI but display an epitope specificity different from antibodies in antiphospholipid syndrome.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Frontiers in immunology - 11(2020) vom: 27., Seite 584241 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Borghi, Maria Orietta [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.12.2020 Date Revised 12.11.2023 published: Electronic-eCollection UpdateOf: medRxiv. 2020 Jul 16;:. - PMID 32588001 Citation Status MEDLINE |
|---|
| doi: |
10.3389/fimmu.2020.584241 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317457926 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317457926 | ||
| 003 | DE-627 | ||
| 005 | 20231226202200.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2020.584241 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1058.xml |
| 035 | |a (DE-627)NLM317457926 | ||
| 035 | |a (NLM)33178218 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Borghi, Maria Orietta |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.12.2020 | ||
| 500 | |a Date Revised 12.11.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a UpdateOf: medRxiv. 2020 Jul 16;:. - PMID 32588001 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Borghi, Beltagy, Garrafa, Curreli, Cecchini, Bodio, Grossi, Blengino, Tincani, Franceschini, Andreoli, Lazzaroni, Piantoni, Masneri, Crisafulli, Brugnoni, Muiesan, Salvetti, Parati, Torresani, Mahler, Heilbron, Pregnolato, Pengo, Tedesco, Pozzi and Meroni. | ||
| 520 | |a Background: Critically ill patients with coronavirus disease 2019 (COVID-19) have a profound hypercoagulable state and often develop coagulopathy which leads to organ failure and death. Because of a prolonged activated partial-thromboplastin time (aPTT), a relationship with anti-phospholipid antibodies (aPLs) has been proposed, but results are controversial. Functional assays for aPL (i.e., lupus anticoagulant) can be influenced by concomitant anticoagulation and/or high levels of C reactive protein. The presence of anti-cardiolipin (aCL), anti-beta2-glycoprotein I (anti-β2GPI), and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies was not investigated systematically. Epitope specificity of anti-β2GPI antibodies was not reported | ||
| 520 | |a Objective: To evaluate the prevalence and the clinical association of aPL in a large cohort of COVID-19 patients, and to characterize the epitope specificity of anti-β2GPI antibodies | ||
| 520 | |a Methods: ELISA and chemiluminescence assays were used to test 122 sera of patients suffering from severe COVID-19. Of them, 16 displayed major thrombotic events | ||
| 520 | |a Results: Anti-β2GPI IgG/IgA/IgM was the most frequent in 15.6/6.6/9.0% of patients, while aCL IgG/IgM was detected in 5.7/6.6% by ELISA. Comparable values were found by chemiluminescence. aPS/PT IgG/IgM were detectable in 2.5 and 9.8% by ELISA. No association between thrombosis and aPL was found. Reactivity against domain 1 and 4-5 of β2GPI was limited to 3/58 (5.2%) tested sera for each domain and did not correlate with aCL/anti-β2GPI nor with thrombosis | ||
| 520 | |a Conclusions: aPL show a low prevalence in COVID-19 patients and are not associated with major thrombotic events. aPL in COVID-19 patients are mainly directed against β2GPI but display an epitope specificity different from antibodies in antiphospholipid syndrome | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a anti-phospholipid antibodies | |
| 650 | 4 | |a autoimmunity | |
| 650 | 4 | |a prothrombin | |
| 650 | 4 | |a thrombosis | |
| 650 | 4 | |a β2-glycoprotein I | |
| 650 | 7 | |a Antibodies, Anticardiolipin |2 NLM | |
| 650 | 7 | |a Epitopes |2 NLM | |
| 650 | 7 | |a Immunoglobulin A |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Immunoglobulin M |2 NLM | |
| 650 | 7 | |a Phosphatidylserines |2 NLM | |
| 650 | 7 | |a beta 2-Glycoprotein I |2 NLM | |
| 650 | 7 | |a Prothrombin |2 NLM | |
| 650 | 7 | |a 9001-26-7 |2 NLM | |
| 700 | 1 | |a Beltagy, Asmaa |e verfasserin |4 aut | |
| 700 | 1 | |a Garrafa, Emirena |e verfasserin |4 aut | |
| 700 | 1 | |a Curreli, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Cecchini, Germana |e verfasserin |4 aut | |
| 700 | 1 | |a Bodio, Caterina |e verfasserin |4 aut | |
| 700 | 1 | |a Grossi, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Blengino, Simonetta |e verfasserin |4 aut | |
| 700 | 1 | |a Tincani, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Franceschini, Franco |e verfasserin |4 aut | |
| 700 | 1 | |a Andreoli, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Lazzaroni, Maria Grazia |e verfasserin |4 aut | |
| 700 | 1 | |a Piantoni, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Masneri, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Crisafulli, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Brugnoni, Duilio |e verfasserin |4 aut | |
| 700 | 1 | |a Muiesan, Maria Lorenza |e verfasserin |4 aut | |
| 700 | 1 | |a Salvetti, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Parati, Gianfranco |e verfasserin |4 aut | |
| 700 | 1 | |a Torresani, Erminio |e verfasserin |4 aut | |
| 700 | 1 | |a Mahler, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Heilbron, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Pregnolato, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Pengo, Martino |e verfasserin |4 aut | |
| 700 | 1 | |a Tedesco, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Pozzi, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Meroni, Pier Luigi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d 2010 |g 11(2020) vom: 27., Seite 584241 |w (DE-627)NLM215811453 |x 1664-3224 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2020 |g day:27 |g pages:584241 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fimmu.2020.584241 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2020 |b 27 |h 584241 | ||